Robert B Sim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3762867/publications.pdf

Version: 2024-02-01

298 papers	20,978 citations	7568 77 h-index	11939 134 g-index
326 all docs	326 docs citations	326 times ranked	16543 citing authors

#	Article	IF	Citations
1	Intrinsic Chemical Reactivity of Activated Human Complement Component C3. Immunobiology, 2022, , 152209.	1.9	2
2	C2 by-pass: Cross-talk between the complement classical and alternative pathways. Immunobiology, 2022, 227, 152225.	1.9	2
3	Mannose-Binding Lectin in Human Health and Disease. , 2021, , 17-47.		1
4	Complement Proteins as Soluble Pattern Recognition Receptors for Pathogenic Viruses. Viruses, 2021, 13, 824.	3.3	12
5	Human Properdin Released By Infiltrating Neutrophils Can Modulate Influenza A Virus Infection. Frontiers in Immunology, 2021, 12, 747654.	4.8	11
6	The Roles and Contributions of the Complement System in the Pathophysiology of Autoimmune Diseases. , 2020, , 263-273.		0
7	Complement-Independent Modulation of Influenza A Virus Infection by Factor H. Frontiers in Immunology, 2020, 11, 355.	4.8	12
8	C4b Binding Protein Acts as an Innate Immune Effector Against Influenza A Virus. Frontiers in Immunology, 2020, 11, 585361.	4.8	20
9	Secretion of functionally active complement factor H related protein 5 (FHR5) by primary tumour cells derived from Glioblastoma Multiforme patients. Immunobiology, 2019, 224, 625-631.	1.9	9
10	Enterococcus faecalis Escapes Complement-Mediated Killing via Recruitment of Complement Factor H. Journal of Infectious Diseases, 2019, 220, 1061-1070.	4.0	8
11	Complement Dependent and Independent Interaction Between Bovine Conglutinin and Mycobacterium bovis BCG: Implications in Bovine Tuberculosis. Frontiers in Immunology, 2019, 9, 3159.	4.8	7
12	Serine proteases of the complement lectin pathway and their genetic variations in ischaemic stroke. Journal of Clinical Pathology, 2018, 71, 141-147.	2.0	13
13	Human Properdin Opsonizes Nanoparticles and Triggers a Potent Pro-inflammatory Response by Macrophages without Involving Complement Activation. Frontiers in Immunology, 2018, 9, 131.	4.8	34
14	Human Properdin Modulates Macrophage: Mycobacterium bovis BCG Interaction via Thrombospondin Repeats 4 and 5. Frontiers in Immunology, 2018, 9, 533.	4.8	15
15	Recombinant chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) protects against LPS-induced lung injury in mice. Clinical Immunology, 2018, 197, 27-33.	3.2	7
16	Potential influences of complement factor H in autoimmune inflammatory and thrombotic disorders. Molecular Immunology, 2017, 84, 84-106.	2.2	22
17	Lectin pathway effector enzyme mannanâ€binding lectinâ€associated serine proteaseâ€2 can activate native complement C3 in absence of C4 and/or C2. FASEB Journal, 2017, 31, 2210-2219.	0.5	43
18	Interactions of the innate immune system with carbon nanotubes. Nanoscale Horizons, 2017, 2, 174-186.	8.0	13

#	Article	IF	Citations
19	Pulmonary surfactant protein SP-D opsonises carbon nanotubes and augments their phagocytosis and subsequent pro-inflammatory immune response. Nanoscale, 2017, 9, 1097-1109.	5.6	17
20	A recombinant two-module form of human properdin is an inhibitor of the complement alternative pathway. Molecular Immunology, 2016, 73, 76-87.	2.2	29
21	Complement Activation. Frontiers in Nanobiomedical Research, 2016, , 303-330.	0.1	1
22	Complement factor H interferes with Mycobacterium bovis BCG entry into macrophages and modulates the pro-inflammatory cytokine response. Immunobiology, 2016, 221, 944-952.	1.9	36
23	Complement research in the 18thâ€“21st centuries: Progress comes with new technology. Immunobiology, 2016, 221, 1037-1045.	1.9	27
24	Complement Deposition on Nanoparticles Can Modulate Immune Responses by Macrophage, B and T Cells. Journal of Biomedical Nanotechnology, 2016, 12, 197-216.	1.1	15
25	Interaction of the Immune System with Nanoparticles. , 2016, , 1678-1685.		0
26	Innate immune humoral factors, C1q and factor H, with differential pattern recognition properties, alter macrophage response to carbon nanotubes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 2109-2118.	3.3	34
27	European Union funded project on the development of a whole complement deficiency screening ELISAâ€”A story of success and an exceptional manager: Mohamed R. Daha. Molecular Immunology, 2015, 68, 63-66.	2.2	3
28	Complement factor H in its alternative identity as adrenomedullin-binding protein 1. Molecular Immunology, 2015, 68, 45-48.	2.2	16
29	Interaction of the Immune System with Nanoparticles. , 2015, , 1-8.		1
30	Low-dose recombinant properdin provides substantial protection againstStreptococcus pneumoniaeandNeisseria meningitidisinfection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5301-5306.	7.1	48
31	A potential anti-coagulant role of complement factor H. Molecular Immunology, 2014, 59, 188-193.	2.2	21
32	The Roles and Contributions of the Complement System in the Pathophysiology of Autoimmune Diseases. , 2014, , 217-227.		0
33	Complement activation by carbon nanotubes and its influence on the phagocytosis and cytokine response by macrophages. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1287-1299.	3.3	57
34	Purification, Quantification, and Functional Analysis of Complement Factor H. Methods in Molecular Biology, 2014, 1100, 207-223.	0.9	5
35	Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16426-16431.	7.1	113
36	Complement Activation. Frontiers in Nanobiomedical Research, 2013, , 357-384.	0.1	7

#	Article	IF	Citations
37	Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration. Human Molecular Genetics, 2013, 22, 4857-4869.	2.9	77
38	Properdin and Factor H: Opposing Players on the Alternative Complement Pathway â€œSee-Sawâ€• Frontiers in Immunology, 2013, 4, 93.	4.8	80
39	Complement Factor I. , 2013, , 2875-2880.		1
40	Human L-ficolin, a Recognition Molecule of the Lectin Activation Pathway of Complement, Activates Complement by Binding to Pneumolysin, the Major Toxin of Streptococcus pneumoniae. PLoS ONE, 2013, 8, e82583.	2.5	20
41	Ligands and receptors of lung surfactant proteins SP-A and SP-D. Frontiers in Bioscience - Landmark, 2013, 18, 1129.	3.0	37
42	Acid-Treated Multi-Walled Carbon Nanotubes Coated with Lung Surfactant Protein SP-A Do Not Induce a Lung Inflammatory Response. Journal of Advanced Microscopy Research, 2013, 8, 93-99.	0.3	2
43	Chemical labelling of active serum thioester proteins for quantification. Immunobiology, 2012, 217, 256-264.	1.9	5
44	Factor H as a regulator of the classical pathway activation. Immunobiology, 2012, 217, 162-168.	1.9	36
45	Human complement Factor H modulates C1q-mediated phagocytosis of apoptotic cells. Immunobiology, 2012, 217, 455-464.	1.9	34
46	The complement system of the goat: Haemolytic assays and isolation of major proteins. BMC Veterinary Research, 2012, 8, 91.	1.9	18
47	Recognition of Carbon Nanotubes by the Human Innate Immune System. Carbon Nanostructures, 2011, , 183-210.	0.1	7
48	High glucose disrupts oligosaccharide recognition function via competitive inhibition: A potential mechanism for immune dysregulation in diabetes mellitus. Immunobiology, 2011, 216, 126-131.	1.9	67
49	Improvement of the expression and purification of Mycobacterium tuberculosis arylamine N-acetyltransferase (TBNAT) a potential target for novel anti-tubercular agents. Protein Expression and Purification, 2011, 80, 246-252.	1.3	15
50	Immune attack on nanoparticles. Nature Nanotechnology, 2011, 6, 80-81.	31.5	42
51	Complement factor I in health and disease. Molecular Immunology, 2011, 48, 1611-1620.	2.2	133
52	Understanding the laminated layer of larval Echinococcus II: immunology. Trends in Parasitology, 2011, 27, 264-273.	3.3	88
53	Complement activation by carbon nanotubes. Advanced Drug Delivery Reviews, 2011, 63, 1031-1041.	13.7	55
54	Complement in health and disease. Advanced Drug Delivery Reviews, 2011, 63, 965-975.	13.7	189

#	Article	IF	Citations
55	Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway. Protein and Cell, 2011, 2, 320-332.	11.0	30
56	Structures of the rat complement regulator CrrY. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 739-743.	0.7	6
57	Effect of Functionalization of Carbon Nanotubes with Psychosine on Complement Activation and Protein Adsorption. Journal of Biomedical Nanotechnology, 2011, 7, 830-839.	1.1	21
58	Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12839-12844.	7.1	118
59	Surface-bound myeloperoxidase is a ligand for recognition of late apoptotic neutrophils by human lung surfactant proteins A and D. Protein and Cell, 2010, 1, 563-572.	11.0	17
60	Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein and Cell, 2010, 1, 664-674.	11.0	52
61	Identification of four novel DC-SIGN ligands on Mycobacterium bovis BCG. Protein and Cell, 2010, 1, 859-870.	11.0	48
62	Complement activation by phospholipids: the interplay of factor H and C1q. Protein and Cell, 2010, 1, 1033-1049.	11.0	47
63	Activation of mannanâ€binding lectinâ€associated serine proteases leads to generation of a fibrin clot. Immunology, 2010, 129, 482-495.	4.4	125
64	Filled and glycosylated carbon nanotubes for in vivo radioemitter localization and imaging. Nature Materials, 2010, 9, 485-490.	27.5	267
65	Impaired Binding of the Age-related Macular Degeneration-associated Complement Factor H 402H Allotype to Bruch's Membrane in Human Retina. Journal of Biological Chemistry, 2010, 285, 30192-30202.	3.4	159
66	The human lung surfactant proteins A (SP-A) and D (SP-D) interact with apoptotic target cells by different binding mechanisms. Immunobiology, 2010, 215, 551-558.	1.9	31
67	Scrapie Pathogenesis: The Role of Complement C1q in Scrapie Agent Uptake by Conventional Dendritic Cells. Journal of Immunology, 2009, 182, 1305-1313.	0.8	32
68	Analogous Interactions in Initiating Complexes of the Classical and Lectin Pathways of Complement. Journal of Immunology, 2009, 182, 7708-7717.	0.8	59
69	A Chemical Approach to Immunoprotein Engineering: Chemoselective Functionalization of Thioester Proteins in Their Native State. ChemBioChem, 2009, 10, 1340-1343.	2.6	5
70	Identification of high-mannose and multiantennary complex-type N-linked glycans containing Î±-galactose epitopes from Nurse shark IgM heavy chain. Glycoconjugate Journal, 2009, 26, 1055-1064.	2.7	11
71	Immunochemical Composition of Cryoglobulins Generated in Stroke. Journal of Clinical Immunology, 2009, 29, 274-281.	3.8	3
72	Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature, 2009, 458, 890-893.	27.8	287

#	Article	IF	Citations
73	Macrophage Scavenger Receptor A Mediates Adhesion to Apolipoproteins A-I and E. Biochemistry, 2009, 48, 11858-11871.	2.5	48
74	Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. Molecular Immunology, 2009, 46, 2745-2752.	2.2	72
75	Towards the crystal structure of intact Human Complement Factor I. Molecular Immunology, 2009, 46, 2864-2865.	2.2	3
76	Multiple routes of complement activation by Mycobacterium bovis BCG. Molecular Immunology, 2009, 46, 3367-3378.	2.2	73
77	Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi. Molecular Immunology, 2009, 47, 426-437.	2.2	82
78	Target Pattern Recognition by Complement Proteins of the Classical and Alternative Pathways. Advances in Experimental Medicine and Biology, 2009, 653, 117-128.	1.6	41
79	879 ROLE OF SOLUBLE LECTIN L-FICOLIN IMMUNE RECOGNITION IN HEPATITIS C VIRUS INFECTION. Journal of Hepatology, 2009, 50, S320.	3.7	0
80	Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood, 2009, 113, 1909-1918.	1.4	183
81	Cryoglobulins as indicators of upregulated immune response in schizophrenia. Clinical Biochemistry, 2008, 41, 355-360.	1.9	22
82	Crystal structure of VC1805, a conserved hypothetical protein from a Vibrio cholerae pathogenicity island, reveals homology to human p32. Proteins: Structure, Function and Bioinformatics, 2008, 71, 1563-1571.	2.6	6
83	The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 1294-1300.	2.3	107
84	Recognition of acetylated oligosaccharides by human L-ficolin. Immunology Letters, 2008, 118, 152-156.	2.5	39
85	Abnormal immune complexes in schizophrenia. Neurochemical Journal, 2008, 2, 329-330.	0.5	1
86	Collectins, collectin receptors and the lectin pathway of complement activation. Clinical and Experimental Immunology, 2008, 97, 4-9.	2.6	30
87	Resistance of the Echinococcus granulosus cyst wall to complement activation: analysis of the role of InsP6deposits. Parasite Immunology, 2008, 30, 354-364.	1.5	15
88	Echinococcus granulosus: The establishment of the metacestode is associated with control of complement-mediated early inflammation. Experimental Parasitology, 2008, 118, 188-196.	1.2	46
89	Enzyme-independent, orientation-selective conjugation of whole human complement C3 to protein surfaces. Journal of Immunological Methods, 2008, 337, 49-54.	1.4	5
90	Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). Molecular Immunology, 2008, 45, 1623-1632.	2.2	106

#	Article	IF	Citations
91	Cellular confocal fluorescence studies and cytotoxic activity of new Zn(ii) bis(thiosemicarbazonato) complexes. Dalton Transactions, 2008, , 2107.	3.3	83
92	Recombinant surfactant protein-D selectively increases apoptosis in eosinophils of allergic asthmatics and enhances uptake of apoptotic eosinophils by macrophages. International Immunology, 2008, 20, 993-1007.	4.0	54
93	Effects of Covalent Functionalization on the Biocompatibility Characteristics of Multi-Walled Carbon Nanotubes. Journal of Nanoscience and Nanotechnology, 2008, 8, 2347-2356.	0.9	51
94	Complement C4B protein in schizophrenia. World Journal of Biological Psychiatry, 2008, 9, 225-230.	2.6	40
95	The Complement System in Schizophrenia. Drug News and Perspectives, 2008, 21, 200.	1.5	123
96	Chapter 6. Complement Control Proteins and Receptors: From FH to CR4. , 2008, , 84-104.		4
97	Molecular Interactions between MASP-2, C4, and C2 and Their Activation Fragments Leading to Complement Activation via the Lectin Pathway. Journal of Biological Chemistry, 2007, 282, 7844-7851.	3.4	51
98	The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells. Journal of Biological Chemistry, 2007, 282, 10894-10900.	3.4	126
99	Human Follicular Lymphoma Cells Contain Oligomannose Glycans in the Antigen-binding Site of the B-cell Receptor. Journal of Biological Chemistry, 2007, 282, 7405-7415.	3.4	117
100	The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins. Annual Review of Immunology, 2007, 25, 21-50.	21.8	1,180
101	Interactions between Neisseria meningitidis and the complement system. Trends in Microbiology, 2007, 15, 233-240.	7.7	114
102	Associative and Structural Properties of the Region of Complement Factor H Encompassing the Tyr402His Disease-related Polymorphism and its Interactions with Heparin. Journal of Molecular Biology, 2007, 368, 564-581.	4.2	44
103	C1q and its growing family. Immunobiology, 2007, 212, 253-266.	1.9	174
104	C1q binding and complement activation by prions and amyloids. Immunobiology, 2007, 212, 355-362.	1.9	48
105	Molecular organization of human Ficolin-2. Molecular Immunology, 2007, 44, 401-411.	2.2	72
106	Mannan-binding lectin associated serine protease 2 (MASP-2) activates prothrombin directly and initiates low-level clotting. Molecular Immunology, 2007, 44, 198.	2.2	0
107	Crystallographic studies of human complement factor I. Molecular Immunology, 2007, 44, 233-234.	2.2	0
108	Prion protein activates and fixes complement directly via the classical pathway: Implications for the mechanism of scrapie agent propagation in lymphoid tissue. Molecular Immunology, 2007, 44, 2997-3004.	2.2	34

#	Article	IF	Citations
109	Towards a structural basis for complement factor H linked age-related macular degeneration. Molecular Immunology, 2007, 44, 3930-3931.	2.2	1
110	Investigation of L-ficolin binding specificity. Molecular Immunology, 2007, 44, 3959.	2.2	0
111	Interactions between factor H and Neisseria meningitidis. Molecular Immunology, 2007, 44, 3980.	2.2	0
112	Evidence for a monomer-dimer equilibrium in native human Factor H. Molecular Immunology, 2007, 44, 3986.	2.2	1
113	Structural basis for complement factor Hâ€"linked age-related macular degeneration. Journal of Experimental Medicine, 2007, 204, 2277-2283.	8.5	168
114	Simultaneous Activation of Complement and Coagulation by MBL-Associated Serine Protease 2. PLoS ONE, 2007, 2, e623.	2.5	220
115	Complement C1qâ€target proteins recognition is inhibited by electric moment effectors. Journal of Molecular Recognition, 2007, 20, 405-415.	2.1	29
116	Binding of pulmonary surfactant proteins to carbon nanotubes; potential for damage to lung immune defense mechanisms. Carbon, 2007, 45, 607-617.	10.3	100
117	Mannan binding lectin and viral hepatitis. Immunology Letters, 2007, 108, 34-44.	2.5	62
118	Expression, purification, cocrystallization and preliminary crystallographic analysis of sucrose octasulfate/human complement regulator factor H SCRs 6â€"8. Acta Crystallographica Section F: Structural Biology Communications, 2007, 63, 480-483.	0.7	14
119	â€˜Greenâ€™ derivatization of carbon nanotubes with Nylon 6 andl-alanine. Journal of Materials Chemistry, 2006, 16, 4420-4426.	6.7	31
120	Complement activation and protein adsorption by carbon nanotubes. Molecular Immunology, 2006, 43, 193-201.	2.2	395
121	Heterogeneity of MBLâ€"MASP complexes. Molecular Immunology, 2006, 43, 1286-1292.	2.2	27
122	Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neuroscience Letters, 2006, 404, 336-341.	2.1	62
123	Discrete MBL-MASP Complexes Show Wide Inter-Individual Variability in Concentration: Data from UK vs Armenian Populations. International Journal of Immunopathology and Pharmacology, 2006, 19, 567-580.	2.1	18
124	Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex. Clinical and Experimental Immunology, 2006, 147, 061127015327009-???.	2.6	38
125	Human complement factor I glycosylation: Structural and functional characterisation of the N-linked oligosaccharides. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 1757-1766.	2.3	27
126	Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunology Letters, 2006, 106, 103-110.	2.5	139

#	Article	IF	Citations
127	Carbohydrate-independent recognition of collagens by the macrophage mannose receptor. European Journal of Immunology, 2006, 36, 1074-1082.	2.9	130
128	Structural Model for the Mannose Receptor Family Uncovered by Electron Microscopy of Endo180 and the Mannose Receptor. Journal of Biological Chemistry, 2006, 281, 8780-8787.	3.4	76
129	Recognition ofCandida albicansby Mannanâ€Binding Lectin In Vitro and In Vivo. Journal of Infectious Diseases, 2006, 193, 1589-1597.	4.0	67
130	Interaction of Mannan Binding Lectin with Î±2 Macroglobulin via Exposed Oligomannose Glycans. Journal of Biological Chemistry, 2006, 281, 6955-6963.	3.4	43
131	His-384 Allotypic Variant of Factor H Associated with Age-related Macular Degeneration Has Different Heparin Binding Properties from the Non-disease-associated Form. Journal of Biological Chemistry, 2006, 281, 24713-24720.	3.4	161
132	Functional Significance of Factor H Binding toNeisseria meningitidis. Journal of Immunology, 2006, 176, 7566-7575.	0.8	219
133	Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nature Immunology, 2005, 6, 920-927.	14.5	363
134	Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. Journal of Immunological Methods, 2005, 296, 187-198.	1.4	270
135	Evolution of innate immune systems. Biochemistry and Molecular Biology Education, 2005, 33, 177-183.	1.2	16
136	Human Serum IgM Glycosylation. Journal of Biological Chemistry, 2005, 280, 29080-29087.	3.4	209
137	A True Autoactivating Enzyme. Journal of Biological Chemistry, 2005, 280, 33435-33444.	3.4	92
138	Human Immunoglobulin Glycosylation and the Lectin Pathway of Complement Activation. Advances in Experimental Medicine and Biology, 2005, 564, 27-43.	1.6	17
139	The Catalytically Active Serine Protease Domain of Human Complement Factor I. Biochemistry, 2005, 44, 6239-6249.	2.5	34
140	Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks. Molecular Immunology, 2005, 42, 31-38.	2.2	33
141	Classical pathway complement activity in schizophrenia. Neuroscience Letters, 2005, 374, 35-37.	2.1	70
142	The Classical Activation Pathway of the Human Complement System Is Specifically Inhibited by Calreticulin from Trypanosoma cruzi. Journal of Immunology, 2004, 172, 3042-3050.	0.8	115
143	Collectins and their role in lung immunity. Journal of Leukocyte Biology, 2004, 75, 27-33.	3.3	50
144	The Glycosylation of Human Serum IgD and IgE and the Accessibility of Identified Oligomannose Structures for Interaction with Mannan-Binding Lectin. Journal of Immunology, 2004, 173, 6831-6840.	0.8	100

#	Article	IF	Citations
145	Mutational Analyses of the Recombinant Globular Regions of Human C1q A, B, and C Chains Suggest an Essential Role for Arginine and Histidine Residues in the C1q-IgG Interaction. Journal of Immunology, 2004, 172, 4351-4358.	0.8	72
146	Disease-associated Mutations in Human Mannose-binding Lectin Compromise Oligomerization and Activity of the Final Protein. Journal of Biological Chemistry, 2004, 279, 21302-21311.	3.4	198
147	Unique precipitation and exocytosis of a calcium salt ofmyo-inositol hexakisphosphate in larvalEchinococcus granulosus. Journal of Cellular Biochemistry, 2004, 93, 1272-1281.	2.6	30
148	Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. FEBS Letters, 2004, 566, 270-274.	2.8	47
149	C1q and tumor necrosis factor superfamily: modularity and versatility. Trends in Immunology, 2004, 25, 551-561.	6.8	392
150	Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Molecular Immunology, 2004, 40, 921-929.	2.2	134
151	Human Complement Factor I Does Not Require Cofactors for Cleavage of Synthetic Substrates. Journal of Immunology, 2004, 173, 367-375.	0.8	35
152	Proteases of the complement system. Biochemical Society Transactions, 2004, 32, 21-27.	3.4	163
153	Mannose-Binding Lectin Is a Disease Modifier in Clinical Malaria and May Function as Opsonin forPlasmodium falciparum- Infected Erythrocytes. Infection and Immunity, 2003, 71, 5245-5253.	2.2	62
154	Natural Substrates and Inhibitors of Mannan-Binding Lectin-Associated Serine Protease-1 and -2: A Study on Recombinant Catalytic Fragments. Journal of Immunology, 2003, 170, 1374-1382.	0.8	202
155	Biochemistry and genetics of mannan-binding lectin (MBL). Biochemical Society Transactions, 2003, 31, 748-752.	3.4	51
156	myo-Inositol hexakisphosphate is a major component of an extracellular structure in the parasitic cestode Echinococcus granulosus. Biochemical Journal, 2002, 362, 297.	3.7	22
157	myo-Inositol hexakisphosphate is a major component of an extracellular structure in the parasitic cestode Echinococcus granulosus. Biochemical Journal, 2002, 362, 297-304.	3.7	32
158	Characterization of complement protein C1q binding to U937 myelomonocytic cells. Biochemical Society Transactions, 2002, 30, A118-A118.	3.4	0
159	Ficolin isolation from human serum. Biochemical Society Transactions, 2002, 30, A118-A118.	3.4	0
160	Activity studies on human complement factor I (FI). Biochemical Society Transactions, 2002, 30, A118-A118.	3.4	0
161	A molecular model for human factor B by constrained scattering modelling. Biochemical Society Transactions, 2002, 30, A119-A119.	3.4	0
162	Glycosylation and the Complement System. Chemical Reviews, 2002, 102, 305-320.	47.7	155

#	Article	IF	Citations
163	In vivo pharmacokinetics of calreticulin S-domain, an inhibitor of the classical complement pathway. International Immunopharmacology, 2002, 2, 415-422.	3.8	8
164	The Biological Functions of MBL-Associated Serine Proteases (MASPs). Immunobiology, 2002, 205, 467-475.	1.9	143
165	Evaluation and clinical interest of mannan binding lectin function in human plasma. Molecular Immunology, 2002, 39, 465-473.	2.2	27
166	Cathepsin K expression in epithelioid and multinucleated giant cells. Journal of Pathology, 2002, 197, 690-690.	4.5	3
167	Activity and regulation of human MBL associated serine protease1(MASP-1). Biochemical Society Transactions, 2001, 29, A129-A129.	3.4	0
168	Assessment of in vivo complement activation on the Echinococcus granulosus hydatid cyst wall. Parasite Immunology, 2001, 23, 655-658.	1.5	7
169	Complement C4bC2 complex formation: an investigation by surface plasmon resonance. BBA - Proteins and Proteomics, 2001, 1544, 96-112.	2.1	28
170	Serine proteases of the complement system. Biochemical Society Transactions, 2000, 28, 545-550.	3.4	85
171	Contribution of C5-mediated mechanisms to host defence against Echinococcus granulosus hydatid infection. Parasite Immunology, 2000, 22, 445-453.	1.5	23
172	How Echinococcus granulosus Deals with Complement. Parasitology Today, 2000, 16, 168-172.	3.0	46
173	Host-derived annexin II at the hostâ€“parasite interface of the Echinococcus granulosus hydatid cyst. Molecular and Biochemical Parasitology, 2000, 110, 171-176.	1.1	16
174	Expression of the Proteinase Specialized in Bone Resorption, Cathepsin K, in Granulomatous Inflammation. Molecular Medicine, 2000, 6, 648-659.	4.4	46
175	Distinct Pathways of Mannan-Binding Lectin (MBL)- and C1-Complex Autoactivation Revealed by Reconstitution of MBL with Recombinant MBL-Associated Serine Protease-2. Journal of Immunology, 2000, 165, 2093-2100.	0.8	184
176	Lung Surfactant Protein A Provides a Route of Entry for Respiratory Syncytial Virus into Host Cells. Viral Immunology, 2000, 13, 125-135.	1.3	48
177	Complement C1q Is Dramatically Up-Regulated in Brain Microglia in Response to Transient Global Cerebral Ischemia. Journal of Immunology, 2000, 164, 5446-5452.	0.8	146
178	Complement-endothelial cell interactions: pathophysiological implications. Molecular Immunology, 2000, 37, 91.	2.2	8
179	ASchistosomaprotein, Sh-TOR, is a novel inhibitor of complement which binds human C2. FEBS Letters, 2000, 470, 131-134.	2.8	34
180	Collectins and innate immunity in the lung. Microbes and Infection, 2000, 2, 273-278.	1.9	40

#	Article	IF	Citations
181	SP-A. , 2000, , 41-45.		0
182	Control of host complement activation by the Echinococcus granulosus hydatid cyst. Immunopharmacology, 1999, 42, 91-98.	2.0	24
183	A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infectionin vitro andin vivo. European Journal of Immunology, 1999, 29, 3478-3484.	2.9	132
184	Activities of the MBL-associated serine proteases (MASPs) and their regulation by natural inhibitors. Molecular Immunology, 1999, 36, 853-861.	2.2	71
185	Complement-endothelial cell interactions: pathophysiological implications. Molecular Immunology, 1999, 36, 261-268.	2.2	78
186	Identification of human complement Factor H as a ligand for L-selectin. Biochemical Journal, 1999, 341, 61-69.	3.7	39
187	Production and functional activity of a recombinant von Willebrand factor-A domain from human complement factor B. Biochemical Journal, 1999, 342, 625-632.	3.7	21
188	Identification of human complement Factor H as a ligand for L-selectin. Biochemical Journal, 1999, 341, 61.	3.7	20
189	A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. European Journal of Immunology, 1999, 29, 3478-3484.	2.9	9
190	Production and functional activity of a recombinant von Willebrand factor-A domain from human complement factor B. Biochemical Journal, 1999, 342, 625.	3.7	7
191	Echinococcus granulosus:An Intraperitoneal Diffusion Chamber Model of Secondary Infection in Mice. Experimental Parasitology, 1998, 90, 270-276.	1.2	19
192	Human complement factor I: its expression by insect cells and its biochemical and structural characterisation. Molecular Immunology, 1998, 35, 503-512.	2.2	16
193	Similarities between complement factor H and Î²2 glycoprotein 1: Phospholipid binding and autoantibodies. Molecular Immunology, 1998, 35, 375.	2.2	5
194	Human complement factor H is an L-selectin ligand. Molecular Immunology, 1998, 35, 376.	2.2	0
195	Interaction of C1q and the Collectins with the Potential Receptors Calreticulin (cClqR/Collectin) Tj ETQq1 1 0.784314 rgBT /Overlock	1.9	87
196	Induction of TNF-Î± release from human buffy coat cells byPseudomonas aeruginosais reduced by lung surfactant protein A. FEBS Letters, 1998, 437, 65-69.	2.8	26
197	Complement, Classical Pathway. , 1998, , 604-612.		2
198	Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in AlzheimerÊ¼s disease. NeuroReport, 1998, 9, 1491-1495.	1.2	31

#	Article	IF	Citations
199	Human Lung Surfactant Protein A Exists in Several Different Oligomeric States: Oligomer Size Distribution Varies between Patient Groups. Molecular Medicine, 1998, 4, 266-275.	4.4	61
200	Mechanism of Action of Anti-C1-Inhibitor Autoantibodies: Prevention of the Formation of Stable C1s-C1-inh Complexes. Molecular Medicine, 1998, 4, 119-128.	4.4	19
201	Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 7544-7549.	7.1	207
202	Interactions between human complement components factor H, factor I and C3b. Biochemical Journal, 1997, 326, 553-561.	3.7	79
203	Comparison of the complement system protein complexes formed by C1q and MBL. Biochemical Society Transactions, 1997, 25, 41S-41S.	3.4	7
204	A secondary C1s interaction site on C1-inhibitor is essential for formation of a stable enzyme-inhibitor complex. FEBS Letters, 1997, 405, 42-46.	2.8	13
205	Role of the distal hinge region of C1-inhibitor in the regulation of C1s activity. FEBS Letters, 1997, 412, 506-510.	2.8	8
206	Degradation of C1-Inhibitor by Plasmin: Implications for the Control of Inflammatory Processes. Molecular Medicine, 1997, 3, 385-396.	4.4	35
207	Mapping the bovine factor H gene to Chromosome 16 by SSCP analysis. Mammalian Genome, 1997, 8, 77-78.	2.2	3
208	The C1q and collectin binding site within C1 q receptor (cell surface calreticulin). Immunopharmacology, 1997, 38, 73-80.	2.0	87
209	Echinococcus granulosus antigen 5 may be a serine proteinase. Parasite Immunology, 1997, 19, 385-385.	1.5	10
210	Antibodies to Î²2 -glycoprotein I-a specific marker for the antiphospholipid syndrome. Clinical and Experimental Immunology, 1997, 109, 304-309.	2.6	83
211	Localisation of the C1q binding site within C 1 q receptor/calreticulin. FEBS Letters, 1996, 397, 245-249.	2.8	53
212	Prediction from sequence comparisons of residues of factor H involved in the interaction with complement component C3b. Biochemical Journal, 1996, 315, 523-531.	3.7	18
213	Comparison of complement activation in vitro by different Echinococcus granulosus extracts. Parasite Immunology, 1996, 18, 371-375.	1.5	17
214	Characterization of Radioiodinated Lung Surfactant Protein a (SP-A) and the Effects of Oxidation on SP-A Quaternary Structure and Activity. Experimental Lung Research, 1996, 22, 467-487.	1.2	17
215	An investigation of the interaction between human complement factor H and C3b. Biochemical Society Transactions, 1995, 23, 53S-53S.	3.4	6
216	Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein. Nature Medicine, 1995, 1, 237-243.	30.7	729

#	Article	IF	Citations
217	Î²-Sheet secondary structure of an LDL receptor domain from complement factor I by consensus structure predictions and spectroscopy. FEBS Letters, 1995, 371, 199-203.	2.8	15
218	Collectins and viral infection. Trends in Microbiology, 1995, 3, 240-244.	7.7	26
219	Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells. Infection and Immunity, 1995, 63, 3360-3366.	2.2	127
220	Collectins: collagenous C-type lectins of the innate immune defense system. Trends in Immunology, 1994, 15, 67-74.	7.5	462
221	The Secondary Structure of the von Willebrand Factor type A Domain in Factor B of Human Complement by Fourier Transform Infrared Spectroscopy. Journal of Molecular Biology, 1994, 238, 104-119.	4.2	70
222	An indirect effect of an antibody on complement deposition and lysis of differently sensitized surrounding cells. Molecular Immunology, 1994, 31, 901-911.	2.2	3
223	Binding sites involved in the formation of the C3(H2O)-factor B complex of the alternative pathway of complement. Biochemical Society Transactions, 1994, 22, 2S-2S.	3.4	10
224	Interactions of carbohydrates and lectins with complement. Biochemical Society Transactions, 1994, 22, 106-111.	3.4	32
225	Interactions in the complement-mediated lysis of blood group AB erythrocytes sensitized simultaneously with anti-A and anti-B monoclonal antibodies. Immunology Letters, 1993, 35, 219-228.	2.5	4
226	Human ?2-glycoprotein I: molecular analysis of DNA and amino acid polymorphism. Human Genetics, 1993, 91, 401-2.	3.8	38
227	Pollen grains bind to lung alveolar type II cells (A549) via lung surfactant protein A (SP-A). Bioscience Reports, 1993, 13, 79-90.	2.4	99
228	Chromosomal mapping of the human interleukin-1 receptor antagonist gene (IL-1RN) and isolation of specific YAC clones. Agents and Actions, 1993, 38, C59-C60.	0.7	5
229	Dye-ligand affinity purification of human complement factor B and Î²2 glycoprotein I. Journal of Immunological Methods, 1993, 157, 25-30.	1.4	21
230	Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance. Journal of Molecular Biology, 1993, 232, 268-284.	4.2	211
231	Characterization of xenopus laevis complement factor I structureâ€"conservation of modular structure except for an unusual insert not present in human factor I. Molecular Immunology, 1993, 30, 1249-1256.	2.2	46
232	[1] Complement factor I and cofactors in control of complement system convertase enzymes. Methods in Enzymology, 1993, 223, 13-35.	1.0	95
233	Genetics and Deficiencies of the Soluble Regulatory Proteins of the Complement System. International Reviews of Immunology, 1993, 10, 65-86.	3.3	53
234	Isolation of a human endothelial cell C1q receptor (C1qR). Journal of Leukocyte Biology, 1993, 53, 179-184.	3.3	47

#	Article	IF	Citations
235	Assignment of apolipoprotein H (APOH: beta-2-glycoprotein I) to human chromosome 17q23â†'qter; determination of the major expression site. Cytogenetic and Genome Research, 1992, 60, 31-33.	1.1	26
236	The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14â€“q21, in the region of the IL-1Î± and IL-1Î² loci. Genomics, 1992, 13, 654-657.	2.9	154
237	Human interleukin-1 receptor antagonist is expressed in liver. FEBS Letters, 1992, 310, 60-62.	2.8	13
238	Human Interleukin-1 receptor antagonist High yield expression in E. coli and examination of cysteine residues. FEBS Letters, 1992, 310, 63-65.	2.8	25
239	Activity, disulphate mapping and structural modelling of the fifth domain of human Î²2 -glycoprotein I. FEBS Letters, 1992, 313, 193-197.	2.8	89
240	In vitro biosynthesis of complement factor I by human endothelial cells. European Journal of Immunology, 1992, 22, 213-217.	2.9	41
241	Interaction of C1q receptor with lung surfactant protein A. European Journal of Immunology, 1992, 22, 1437-1445.	2.9	139
242	Oligomeric domain structure of human complement factor H by x-ray and neutron solution scattering. Biochemistry, 1991, 30, 2847-2857.	2.5	62
243	Three-dimensional structure of a complement control protein module in solution. Journal of Molecular Biology, 1991, 219, 717-725.	4.2	240
244	Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.4	62
245	Length variation within intron 2 of the human IL-1 receptor antagonist protein gene (IL1RN). Nucleic Acids Research, 1991, 19, 5095-5095.	14.5	38
246	C1: molecular interactions with activating systems. Trends in Immunology, 1991, 12, 307-311.	7.5	84
247	An angle-variable three-dimensional pulsed field gel electrophoresis system. Analytical Biochemistry, 1991, 192, 32-38.	2.4	10
248	Human leukocyte C1q receptor binds other soluble proteins with collagen domains.. Journal of Experimental Medicine, 1990, 172, 955-959.	8.5	279
249	Interaction of C1q, and other proteins containing collagen-like domains, with the C1q receptor. Biochemical Society Transactions, 1990, 18, 1145-1148.	3.4	30
250	Molecular modeling of human complement component C4 and its fragments by x-ray and neutron solution scattering. Biochemistry, 1990, 29, 1167-1175.	2.5	29
251	Studies on the sensitivity to complementâ€mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). British Journal of Haematology, 1989, 73, 248-253.	2.5	96
252	Lack of abnormal sensitivity to complement-mediated lysis in erythrocytes deficient only in decay accelerating factor. Biochemical Society Transactions, 1989, 17, 514-514.	3.4	6

#	Article	IF	Citations
253	Sequence polymorphism of human complement factor H. Immunogenetics, 1988, 27, 211-214.	2.4	57
254	Structure, Organization, and Regulation of the Complement Genes. Annual Review of Immunology, 1988, 6, 161-195.	21.8	176
255	A study of the structure of human complement component factor H by Fourier transform infrared spectroscopy and secondary structure averaging methods. Biochemistry, 1988, 27, 4004-4012.	2.5	104
256	Appearance of acceptor-bound C3b on HLA-DR positive macrophages and on stimulated U937 cells; Inhibition of FcÎ³-receptors by the covalently fixed C3 fragments. Molecular Immunology, 1988, 25, 295-303.	2.2	19
257	Interferon gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture.. Journal of Experimental Medicine, 1988, 168, 1917-1922.	8.5	101
258	Studies on the isolation of human C1q-receptor. Biochemical Society Transactions, 1988, 16, 735-736.	3.4	14
259	mRNA coding for a truncated form of human complement factor H. Biochemical Society Transactions, 1987, 15, 651-652.	3.4	13
260	Monoclonal antibodies against complement component C3. Biochemical Society Transactions, 1987, 15, 653-654.	3.4	3
261	Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 8628-8632.	7.1	1,270
262	The functions and relationships of Ty-VLP proteins in yeast reflect those of mammalian retroviral proteins. Cell, 1987, 49, 111-119.	28.9	162
263	Structure and specificity of complement receptors. Immunology Letters, 1987, 14, 183-190.	2.5	25
264	Sequence analysis of a cDNA clone encoding the C-terminal end of human complement factor H. Bioscience Reports, 1987, 7, 201-207.	2.4	7
265	Inhibitory effect of Zn2+ ions on the degradation of the complement activation fragment C3b. Biochemical Society Transactions, 1986, 14, 73-74.	3.4	12
266	Ligand binding by the pl50,95 antigen of U937 monocytic cells: properties in common with complement receptor type 3 (CR3). European Journal of Immunology, 1986, 16, 1117-1123.	2.9	98
267	Immunoblotting analysis of the peptide chain structure of the physiological breakdown products of the third component of human complement. Electrophoresis, 1986, 7, 379-386.	2.4	12
268	Complement system proteins which interact with C3b or C4b A superfamily of structurally related proteins. Trends in Immunology, 1986, 7, 230-234.	7.5	232
269	An IgG autoantibody which inactivates C1Â¯-inhibitor. Nature, 1986, 323, 722-724.	27.8	184
270	Molecular modelling of human complement component C3 and its fragments by solution scattering. FEBS Journal, 1986, 157, 155-168.	0.2	61

#	Article	IF	Citations
271	Partial characterization of human complement factor H by protein and cDNA sequencing: Homology with other complement and non-complement proteins. Bioscience Reports, 1986, 6, 65-72.	2.4	31
272	Molecular Biology of the Human Complement Class III Products of the MHC: Factor I and Its Cofactors. , 1986, , 299-313.		0
273	Expression of complement factor H on the cell surface of the human monocytic cell line U937. European Journal of Immunology, 1985, 15, 935-941.	2.9	51
274	Application of the immunoblotting technique to the study of single protein species in complex biological fluids: A model study with alpha-2-macroglobulin. Electrophoresis, 1985, 6, 227-234.	2.4	7
275	Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum.. Journal of Experimental Medicine, 1985, 162, 324-331.	8.5	309
276	The generation of active fragments of complement receptor type 2 by trypsin digestion. FEBS Letters, 1985, 189, 195-201.	2.8	8
277	Interaction of human monocytes, macrophages, and polymorphonuclear leukocytes with zymosan in vitro. Role of type 3 complement receptors and macrophage-derived complement.. Journal of Clinical Investigation, 1985, 76, 2368-2376.	8.2	99
278	The Effect of Danazol on the Production of C1 Inhibitor in the Guinea Pig. Complement (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46	0.9	9
279	Localisation of a group of antigenic sites in complement component C3, and identification of a new fragmentation pattern. BBA - Proteins and Proteomics, 1984, 789, 119-127.	2.1	2
280	Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice. International Journal of Cancer, 1984, 33, 683-687.	5.1	12
281	Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan.. Journal of Experimental Medicine, 1984, 159, 244-260.	8.5	208
282	Role of complement receptor CR1 in the breakdown of soluble and zymosan-bound C3b. Biochemical Society Transactions, 1984, 12, 781-782.	3.4	17
283	AUTOLYTIC FRAGMENTATION OF COMPLEMENT COMPONENTS C3 AND C4 AND ITS RELATIONSHIP TO COVALENT BINDING ACTIVITY. Annals of the New York Academy of Sciences, 1983, 421, 259-276.	3.8	32
284	WM1 monoclonal antibody inhibits the binding of activated C3 to surfaces. Molecular Immunology, 1982, 19, 1402.	2.2	0
285	Pattern of degradation of human complement fragment, C3b. FEBS Letters, 1981, 132, 55-60.	2.8	83
286	The Covalent Interactions of Complement Components and Other Proteins with Antibodies and Cell Surfaces. , 1981, 2, 224-230.		1
287	A monoclonal antibody against human complement component C3: the production of C3 by human cellsin vitro. European Journal of Immunology, 1981, 11, 140-146.	2.9	37
288	Intramolecular general acid catalysis in the binding reactions of Î±2 and complement components C3 and C4. Bioscience Reports, 1981, 1, 461-468.	2.4	42

#	Article	IF	Citations
289	[2] The first component of human complementâ€"C1. Methods in Enzymology, 1981, 80 Pt C, 6-16.	1.0	20
290	[4] The human complement system serine proteases and and their proenzymes. Methods in Enzymology, 1981, 80 Pt C, 26-42.	1.0	53
291	[5] Preparation and properties of human inhibitor. Methods in Enzymology, 1981, 80 Pt C, 43-54.	1.0	56
292	Kinetics of reaction of human C-inhibitor with the human complement system proteases Cr and Cs. Biochimica Et Biophysica Acta - Biomembranes, 1980, 612, 433-449.	2.6	76
293	Hydrodynamic Parameters of the Detergent-Solubilised Hydrogenase from Paracoccus denitrificans. FEBS Journal, 1979, 97, 119-126.	0.2	17
294	Interaction of C-inhibitor with the Cr and Cs subcomponents in human C. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1979, 576, 151-162.	1.7	52
295	Interaction of 125 I-labelled complement subcomponents Cr and Cs with protease inhibitors in plasma. FEBS Letters, 1979, 97, 111-115.	2.8	142
296	Differential elution of Clq, ClÌ„r and ClÌ„s from human CT bound to immune aggregates. use in the rapid purification of ClÌ„ sub-components. Molecular Immunology, 1979, 16, 445-450.	2.2	150
297	A simplified procedure for the purification of C1Ì„-inactivator from human plasma Interaction with complement subcomponents C1Ì„r and C1Ì„s. FEBS Letters, 1977, 79, 45-50.	2.8	76
298	Isolation and Comparison of the Proenzyme and Activated Forms of the Human Serum Complement Subcomponents C1r and C1s. Biochemical Society Transactions, 1976, 4, 127-129.	3.4	32